• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of single versus dual antiplatelet therapy after TAVR: A systematic review and meta ‐analysis
ConclusionIn this small meta‐analysis of DAPT versus SAPT after TAVR, DAPT did not prevent stroke, myocardial infarction or death while the risk of bleeding was higher. Results from ongoing trials are awaited to determine the best anti‐thrombotic approach after TAVR.
Source: Catheterization and Cardiovascular Interventions - March 8, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Hitesh Raheja, Aakash Garg, Sunny Goel, Kinjal Banerjee, Gerald Hollander, Jacob Shani, Stephanie Mick, Jonathan White, Amar Krishnaswamy, Samir Kapadia Tags: VALVULAR AND STRUCTURAL HEART DISEASES Source Type: research

Aspirin and clopidogrel high on ‐treatment platelet reactivity and genetic predictors in peripheral arterial disease
ConclusionClopidogrel HoTPR was significantly associated with TVR, while aspirin HoTPR was not associated with adverse clinical outcomes in patients with PAD.
Source: Catheterization and Cardiovascular Interventions - February 7, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Khung ‐Keong Yeo, Ehrin J. Armstrong, Javier E. López, Debbie C. Chen, Gregory G. Westin, Chin‐Shang Li, David Anderson, Amy Hua, Anil Singapuri, Ezra A. Amsterdam, Nipavan Chiamvimonvat, John R. Laird Tags: PERIPHERAL VASCULAR DISEASE Source Type: research

Thromboembolism after WATCHMANTM in a clopidogrel non ‐responder: A case for concern?
Abstract Atrial fibrillation (AF) is associated with an increased risk of stroke and thromboembolism (TE). The WATCHMANTM left atrial appendage (LAA) closure device is indicated to reduce the risk of TE from the LAA in patients with non‐valvular AF. Here, we present a case of a patient with device‐related thrombus who suffered a TE event two months after WATCHMANTM LAA closure and two weeks after switching from aspirin plus warfarin to aspirin plus clopidogrel therapy. Laboratory investigation identified the patient to be hypercoagulable and to be a non‐responder to clopidogrel therapy. We discuss the potential role ...
Source: Catheterization and Cardiovascular Interventions - November 11, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Ganesh Venkataraman, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel Tags: VALVULAR AND STRUCTURAL HEART DISEASES Source Type: research

Clinical outcomes associated with per ‐operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta‐analysis
Conclusion: Our analysis suggests that planned short‐term discontinuation in the appropriate clinical setting appears to be safe in the correct clinical setting with no increased risk of thrombotic events and with a decreased risk of bleeding. © 2016 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - September 23, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Faraz Khan Luni, Haris Riaz, Abdur Rahman Khan, Talha Riaz, Muhammad Husnain, Irbaz Bin Riaz, Muhammad Shahzeb Khan, Mohammed Taleb, Yusuf Kanjwal, Christopher J. Cooper, Sadik A. Khuder Tags: Coronary Artery Disease Source Type: research

Results of percutaneous closure of patent foramen ovale with the GORE® septal occluder
ConclusionPFO closure with the GSO is accompanied by a high technical success rate and closure rates similar to other currently used devices. The incidence of AF was higher than reported with most other devices. This may be a chance finding but warrants further investigation in larger trials. © 2013 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - January 20, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Meike Knerr, Stefan Bertog, Laura Vaskelyte, Ilona Hofmann, Horst Sievert Tags: Valvular and Structural Heart Diseases Source Type: research

Results of percutaneous closure of patent foramen ovale with the GORE ® Septal Occluder
Conclusion. PFO closure with the GSO is accompanied by a high technical success rate and closure rates similar to other currently used devices. The incidence of atrial fibrillation was higher than reported with most other devices. This may be a chance finding but warrants further investigation in larger trials. © 2013 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - December 10, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Meike Knerr, Stefan Bertog, Laura Vaskelyte, Ilona Hofmann, Horst Sievert Tags: Original Study Source Type: research